1-acetyl-piperidine-4-carboxylic acid methyl ester | 126291-66-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-acetyl-piperidine-4-carboxylic acid methyl ester
• 英文别名: 1-Acetyl-piperidin-4-carbonsaeure-methylester；methyl 1-acetylpiperidine-4-carboxylate
• CAS: 126291-66-5
• 化学式: C₉H₁₅NO₃
• mdl: MFCD02862113
• 分子量: 185.223
• InChiKey: XCGYEEUWADWLCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-acetyl-piperidine-4-carboxylic acid methyl ester 在 lithium aluminium tetrahydride 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 (1-乙基哌啶-4-基)甲醇
  参考文献：
  名称：

  [EN] PURINE DERIVATIVES USEFUL AS ANTI - CANCER AGENTS
  [FR] COMPOSÉS ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  公开号：

  WO2010111406A3
• 作为产物：
  描述：

  4-哌啶甲酸甲酯 、 乙酸酐 生成 1-acetyl-piperidine-4-carboxylic acid methyl ester
  参考文献：
  名称：

  Chemotherapy of Experimental Tuberculosis. VIII. The Synthesis of Acid Hydrazides, their Derivatives and Related Compounds^1,2

  摘要：

  DOI：

  10.1021/ja01104a046

文献信息

• NOVEL OLEFIN DERIVATIVE
  申请人：Matsumura Akira

  公开号：US20150246938A1

  公开（公告）日：2015-09-03

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

  本发明的目的是提供具有ACC2抑制活性的新型化合物。此外，本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物： 其中R1是取代或未取代的芳基等， R2各自独立为氢，取代或未取代的烷基等， R3各自独立为氢，取代或未取代的烷基等， n是0到3的整数， R12是氢，取代或未取代的烷基等， 环A是芳香碳环或芳香杂环， R9是取代或未取代的烷基，取代或未取代的烯基等， m是0到4的整数， R4和R5各自独立为氢，取代或未取代的烷基等， R6是取代或未取代的烷基，取代或未取代的烯基等， R13是氢，取代或未取代的烷基等， X5是键等， R7是氢或取代或未取代的烷基， R8是取代或未取代的烷基碳酰，取代或未取代的烯基碳酰等。
• [EN] COMPOUND LIBRARIES OF N-(AMINOCARBONYL)-PIPERIDINE-4-CARBOXAMIDE DERIVATIVES CAPABLE OF BINDING TO G-PROTEIN COUPLED RECEPTORS<br/>[FR] BANQUE DE COMPOSES CONTENANT DES DERIVES DE N-(AMINOCARBONYL)-PIPERIDINE-4-CARBOXAMIDE, CAPABLES DE SE FIXER AUX RECEPTEURS COUPLES A LA PROTEINE G
  申请人：BIOFOCUS PLC

  公开号：WO2004058259A1

  公开（公告）日：2004-07-15

  The present invention provides a compound library targeted to receptors with a requirement for a positively charged amine in their structure activity relationships. It is designed to produce both agonists and antagonists and so is expected to be especially useful in producing ligands for orphan receptors. The library is designed around an acylurea coupled to a piperidine moiety. A combination of specific motifs R2 and R1 are appended from the central scaffold and are designed to pick up different interactions at a receptor site. The library comprises or consists of a set of structurally related compounds of general formula (I).

  本发明提供了一个针对需要带正电胺基的受体的化合物库，该化合物库旨在产生激动剂和拮抗剂，因此预计在制备孤儿受体的配体方面特别有用。该库围绕一个酰基脲偶联到哌啶基团而设计。从中心支架附加特定基团R2和R1的组合被设计为在受体位点捕获不同的相互作用。该库包括或由一组结构相关的通用式(I)化合物组成。
• Fused Triazole Tachykinin Receptor Antagonists
  申请人：DeVita Robert J.

  公开号：US20090221611A1

  公开（公告）日：2009-09-03

  The present invention is directed to certain fused triazole compounds which are useful as neurokinin-1 (NK-I) receptor antagonists, and inhibitors of tachykinin and in particular substance P- The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

  本发明涉及某些融合的三唑化合物，它们可用作神经激肽-1（NK-I）受体拮抗剂和快速激肽，特别是物质P的抑制剂。本发明还涉及包含这些化合物作为活性成分的制药配方以及这些化合物及其配方在治疗某些疾病，包括呕吐、尿失禁、抑郁症和焦虑症方面的用途。
• USE OF PIPERIDINE ESTER DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS COMPRISING IT
  申请人：Muller Benoit

  公开号：US20120282197A1

  公开（公告）日：2012-11-08

  The present invention relates to the use of at least one piperidine ester derivative of formula (I) below: in which: R 1 is a linear or branched C 1 -C 12 alkyl radical, R 2 is a linear or branched C 1 -C 20 alkyl radical, with the proviso that the sum of the carbon atoms for R 1 and R 2 is between 2 and 22, in a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase and at least one lipophilic active agent, and containing no dibenzoylmethane-type UV screening agent, as a solvent for said active agent in said liquid fatty phase and/or as an agent improving the solubility of said active agent in said fatty phase. The present invention also relates to a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase, characterized in that it comprises at least one piperidine ester derivative of formula (I) as defined above and in that it does not contain a dibenzoylmethane-type UV screening agent.

  本发明涉及使用公式（I）中至少一种哌啶酯衍生物： 其中：R1是直链或支链C1-C12烷基基团，R2是直链或支链C1-C20烷基基团，但R1和R2的碳原子总和在2到22之间，作为一种溶剂用于至少一种脂溶性活性剂在至少一种液态脂肪相中，且不含二苯甲酰甲烷类型的紫外线筛选剂。本发明还涉及一种组合物，其中至少包含一种液态脂肪相，在化妆品可接受的介质中，其特征在于其包含上述公式（I）中的至少一种哌啶酯衍生物，并且不含二苯甲酰甲烷类型的紫外线筛选剂。
• THERAPEUTIC AGENT FOR ERECTION FAILURE
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP0992240A1

  公开（公告）日：2000-04-12

  A therapeutic agent for erection dysfunction and gynecoid incompetence, which is free from the problems involved in oral administration and direct injection, is safe, and exhibits excellent effect. A therapeutic agent for erection dysfunction and gynecoid incompetence for intranasal administration, percutaneous administration, or mucosal administration, such as oral mucosal administration or penis mucosal administration, characterized by containing as the active ingredient at least one compound having cyclic GMP phosphodiesterase inhibitory activity or salt thereof.

  一种治疗勃起功能障碍和妇科功能不全的药剂，它没有口服给药和直接注射给药的问题，安全且效果极佳。一种用于鼻内给药、经皮给药或粘膜给药（如口腔粘膜给药、阴茎粘膜给药）的勃起功能障碍和妇科功能不全治疗剂，其特征在于活性成分中至少含有一种具有环 GMP 磷酸二酯酶抑制活性的化合物或其盐。